Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Más filtros

Banco de datos
Tipo del documento
Asunto de la revista
País de afiliación
Intervalo de año de publicación
1.
Ren Fail ; 46(1): 2356708, 2024 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-38803220

RESUMEN

As no unified treatment protocol or evidence yet exists for plasmapheresis without plasma, this study explored the outcomes of using 4% human albumin (ALB) solution as a replacement solution in patients undergoing plasma exchange for multiple myeloma (MM) patients with acute kidney injury (AKI). This study was prospectively registered (ChiCTR2000030640 and NCT05251896). Bortezomib-based chemotherapy plus therapeutic plasmapheresis (TPP) with 4% human ALB solution was assessed for three years in patients with MM aged >18 years, with AKI according to the Kidney Disease Improving Global Outcomes criteria, and without previous renal impairment from other causes. The primary endpoints were changes in renal function over 18 weeks and survival outcomes at 36 months. The secondary endpoints were the incidence of adverse reactions and symptom improvement. Among the 119 patients included in the analysis, 108 experienced renal reactions. The M protein (absolute changes: median -12.12%, interquartile ranges (IQRs) -18.62 to -5.626) and creatine (median -46.91 µmol/L, IQR -64.70 to -29.12) levels decreased, whereas the estimated glomerular filtration rate (eGFR) increased (median 20.66 mL/(min·1.73 m2), IQR 16.03-25.29). Regarding patient survival, 68.1% and 35.3% of patients survived for >12 and >36 months, respectively. The three symptoms with the greatest relief were urine foam, poor appetite, and blurred vision. All 11 patients (7.6%) who experienced mild adverse reactions achieved remission. In conclusion, in MM patients with AKI, plasma-free plasmapheresis with 4% human ALB solution and bortezomib-based chemotherapy effectively alleviated light chain damage to kidney function while improving patient quality of life.


Asunto(s)
Lesión Renal Aguda , Bortezomib , Tasa de Filtración Glomerular , Mieloma Múltiple , Plasmaféresis , Humanos , Mieloma Múltiple/complicaciones , Mieloma Múltiple/terapia , Lesión Renal Aguda/terapia , Lesión Renal Aguda/etiología , Plasmaféresis/métodos , Masculino , Femenino , Persona de Mediana Edad , Estudios Prospectivos , Anciano , Bortezomib/administración & dosificación , Bortezomib/uso terapéutico , Prueba de Estudio Conceptual , Albúmina Sérica Humana/análisis , Albúmina Sérica Humana/administración & dosificación , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Protocolos de Quimioterapia Combinada Antineoplásica/efectos adversos , Resultado del Tratamiento , Adulto , Terapia Combinada , Proteínas de Mieloma
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA